Brief: Hungary's Richter announces new long-term strategy

Richter Gedeon Vegyeszeti Gyar Nyrt

05/03/2025 07:16

March 5 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU says:

BOARD OF DIRECTORS APPROVED NEW LONG-TERM STRATEGY

STRATEGY DEFINES PLANS TO NAVIGATE FOR SUCCESS AMIDST THE LOSS OF EXCLUSIVITY OF CARIPRAZINE TOWARDS THE END OF THE DECADE

IN NEUROPSYCHIATRY (CNS) RESEARCH IS UNDERWAY TO FIND AND DEVELOP THE NEXT BLOCKBUSTER MOLECULE

WANTS TO FURTHER BUILD ITS PORTFOLIO OF INNOVATIVE TREATMENTS ACROSS EXISTING AND NEW THERAPEUTIC SEGMENTS

EXPECTS TO DOUBLE ITS REVENUES FROM WOMEN'S HEALTHCARE  AS WELL AS ITS R&D INVESTMENTS

EXPECTS WOMEN'S HEALTHCARE TO BECOME THE LARGEST REVENUE AND EARNING CONTRIBUTOR BY 2025

WILL FOCUS ON MAXIMIZING THE VALUE OF CARIPRAZINE BY ITS LOSS OF EXCLUSIVITY

EXPECTS TO INCREASE ITS NON-CNS REVENUES AT AN ANNUAL AVERAGE GROWTH RATE OF 7-8% TO AROUND EUR 3.2-3.5BN BY 2035

Source text: [https://bse.hu/newkibdata/129208155/Strategy2035_5Mar2025_EN.pdf]

Further company coverage: GDRB.BU

 (Reporting by Anita Komuves)

 ((KOMUVES.Anita@thomsonreuters.com;))